Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of guselkumab and golimumab combination induction and maintenance therapy in moderately to severely active ulcerative colitis
CTR20233646Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of guselkumab, golimumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Started Apr 2024; status: active.
02
Drugs
guselkumabgolimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20233646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233646.